Prospective, non-interventional, multi-center study. The observation period for each subject covers the treatment period with Gadovist®. For each patient, the treating physician or nurse documents demographics, medical data, safety parameters and treatment signs and symptoms at the visit. Patients with severe renal impairment will be followed-up after 3 month by phone call from the investigator if in line with routine practice. Data audit/monitoring by source data verification will be done in a subset of sites and patients
Evaluate the safety and tolerability of Gadovist in patients requiring contrast-enhanced MRI.
Study Type
OBSERVATIONAL
Enrollment
23,775
Patients requiring contrast enhanced MRI using Gadovist. Administration of Gadovist at the discretion of the attending physician.
Unnamed facility
Many Locations, Bosnia and Herzegovina
Unnamed facility
Many Locations, Canada
Unnamed facility
Many Locations, China
Unnamed facility
Many Locations, Czechia
Unnamed facility
Many Locations, France
Unnamed facility
Many Locations, Germany
Unnamed facility
Many Locations, Greece
Unnamed facility
Many Locations, Hong Kong
Unnamed facility
Many Locations, Hungary
Unnamed facility
Many Locations, Italy
...and 10 more locations
Number of Adverse Event Collection / Calculation of Adverse Event rates in Study population and subgroups
Time frame: 1 day
Analysis of Adverse Event Collection rates according to age, gender, concomitant diseases and risk factors, dose administered.
Time frame: 1 day
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.